Sionna inks $191M IPO for cystic fibrosis pipeline as Aardvark eyes $89M for its own listing

Cystic fibrosis biotech Sionna Therapeutics will raise $191 million in its upsized Nasdaq debut on Friday, and metabolic disease biotech Aardvark Therapeutics outlined plans for a potential $89 million IPO. ...